The Noramco Group Invests $25M into Halo Pharma Facility in NJ

URLhttps://www.contractpharma.com/breaking-news/the-n
SourceContract Pharma
Date Published03/10/2025
Author NameCharlie Sternberg

Additional Reshoring Information:

Company/Division name Halo Industries
Parent companyNoramco
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2025
Capital investment ($):25
City reshored to:Whippany
State(s) reshored to:NJ
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharma and injectibles
What domestic positive factors made reshoring more attractive?Automation/technology, Eco-system synergies, Impact on domestic economy, Proximity to customers/market, Raw Materials Cost
Find Reshoring Articles